Neumora Therapeutics Inc. (NASDAQ: NMRA) is -17.60% lower on its value in year-to-date trading and has touched a low of $8.33 and a high of $21.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NMRA stock was last observed hovering at around $16.49 in the last trading session, with the day’s loss setting it -2.44%.
Currently trading at $14.05, the stock is -3.29% and 9.94% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.62 million and changing -14.80% at the moment leaves the stock 9.69% off its SMA200. NMRA registered 41.78% gain for a year compared to 6-month gain of 34.97%. The firm has a 50-day simple moving average (SMA 50) of $12.7801 and a 200-day simple moving average (SMA200) of $12.808775.
The stock witnessed a 8.75% loss in the last 1 month and extending the period to 3 months gives it a 17.67%, and is -9.94% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.88% over the week and 7.30% over the month.
Neumora Therapeutics Inc. (NMRA) has around 124 employees, a market worth around $2.25B and $0.00M in sales. Distance from 52-week low is 68.67% and -33.10% from its 52-week high. The company has generated returns on investments over the last 12 months (-71.91%).
The EPS is expected to grow by 59.37% this year.
Neumora Therapeutics Inc. (NMRA) Top Institutional Holders
137.0 institutions hold shares in Neumora Therapeutics Inc. (NMRA), with institutional investors hold 85.79% of the company’s shares. The shares outstanding are 158.83M, and float is at 54.91M with Short Float at 17.63%. Institutions hold 61.77% of the Float.
Neumora Therapeutics Inc. (NMRA) Insider Activity
The most recent transaction is an insider sale by Fust Matthew K, the company’s Director. SEC filings show that Fust Matthew K sold 14,049 shares of the company’s common stock on Oct 18 ’24 at a price of $17.03 per share for a total of $0.24 million. Following the sale, the insider now owns 20100.0 shares.
Neumora Therapeutics Inc. disclosed in a document filed with the SEC on Oct 17 ’24 that Fust Matthew K (Director) sold a total of 7,739 shares of the company’s common stock. The trade occurred on Oct 17 ’24 and was made at $17.01 per share for $0.13 million. Following the transaction, the insider now directly holds 20100.0 shares of the NMRA stock.
Still, SEC filings show that on Oct 18 ’24, Fust Matthew K (Director) Proposed Sale 14,049 shares at an average price of $17.03 for $0.24 million. The insider now directly holds shares of Neumora Therapeutics Inc. (NMRA).
